Innate Pharma Showcases Oncology Portfolio Data at SITC 2024

Innate Pharma SA, a biotechnology company based in Marseille, France, has unveiled new preclinical data that underpin the clinical progress of its advanced antibody-drug conjugate (ADC) and groundbreaking tetra-specific ANKET® platform. These findings will be showcased at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024, held in Houston, Texas, and virtually.

The company's Chief Scientific Officer, Pr. Eric Vivier, expressed enthusiasm about presenting their latest preclinical results. The highlights include IPH6501, a tetra-specific NK cell engager, and IPH4502, an innovative ADC targeting Nectin-4. Vivier emphasized that these breakthroughs signify their dedication to advancing the frontier of next-generation immunotherapies and mark considerable advancements in their drug development efforts.

The SITC Annual Meeting will feature detailed presentations on these developments. The "Harnessing NK Cells in Cancer Therapies" session will include an oral presentation by Eric Vivier on November 8, 2024. The session will delve into the preclinical characterization of IPH6501, a novel IL2v-armed tetra-specific NK cell engager targeting CD20 in relapsed or refractory B cell Non-Hodgkin Lymphoma subtypes and post-CAR-T therapy. Additionally, IPH4502 will be highlighted through a poster presentation on November 9, 2024, detailing its design as a next-generation ADC aimed at Nectin-4 expressing tumors.

IPH4502 is a unique topoisomerase I inhibitor ADC conjugated to exatecan, targeting Nectin-4, a cell membrane protein notably overexpressed in various solid tumors such as urothelial, breast, lung, ovarian, and pancreatic cancers, while having limited presence in normal tissues. Preclinical models have shown that IPH4502 is well tolerated and exhibits significant anti-tumor efficacy. In September 2024, the U.S. Food and Drug Administration approved Innate's investigational new drug application, paving the way for a Phase 1 clinical study of IPH4502 in solid tumors expressing Nectin-4.

Moreover, IPH6501 represents the first antibody-based NK cell engager therapeutic that co-engages activating receptors on NK cells, IL-2R through a human IL-2 variant, and a tumor antigen (CD20) through a single molecule. This innovative approach aims to provide proliferation and activation signals to NK cells, enhancing their cytotoxic activity against CD20-expressing malignant cells. Preclinical studies have shown that IPH6501 outperforms current benchmark antibodies in anti-tumor efficacy. It is currently under evaluation in a Phase 1/2 multicenter trial, focusing on its safety and tolerability in patients with relapsed and/or refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.

Innate Pharma's commitment to developing innovative immunotherapies is reflected in their comprehensive pipeline. Their primary proprietary program, lacutamab, is in advanced development stages for cutaneous T cell lymphomas and peripheral T cell lymphomas. They are also working in collaboration with AstraZeneca on monalizumab for non-small cell lung cancer. Their ANKET® platform continues to show promise with multiple drug candidates targeting various tumor types, alongside IPH4502, a differentiated ADC for solid tumors.

In addition to their robust drug development pipeline, Innate Pharma has established partnerships with leading biopharmaceutical companies such as Sanofi and AstraZeneca, and collaborates with top research institutions to accelerate innovation and deliver benefits to patients. With headquarters in Marseille and an office in the US, Innate Pharma is publicly traded on both Euronext Paris and Nasdaq in the US.

Innate Pharma's latest findings underscore their relentless pursuit of cutting-edge immunotherapy solutions, aiming to make significant strides in cancer treatment and improve patient outcomes worldwide.